San Antonio Breast Cancer Symposium begins 36th year announcing medical advances in San Antonio

SAN ANTONIO (December 6, 2013) – The San Antonio Breast Cancer Symposium next week will highlight the latest advances in research and treatment of breast cancer from around the world.

From Dec. 10-14, more than 7,000 physicians, researchers and advocates from every continent except Antarctica will be in downtown San Antonio to attend this meeting, one of the largest breast cancer symposiums. Its estimated economic impact in 2012 alone was more than $9 million, with similar figures expected this year at the 36th annual SABCS.

“We have speakers addressing novel approaches to breast cancer treatment, and also important public health issues such as screening and overdiagnosis,” said Ismail Jatoi, M.D., chief of surgical oncology at The University of Texas Health Science Center and a member of the SABCS Executive Committee.

Local talent will be out in force as well. Numerous Health Science Center faculty members will exhibit their newest research at the symposium, sharing investigations into everything from new drug development to prevention research.

The SABCS is presented by the Cancer Therapy & Research Center at the UT Health Science Center, the American Association for Cancer Research and Baylor College of Medicine.

During the week, four press conferences will highlight important news that will be revealed at the meeting. They will be held in Room 217D on the following days/times:

Wednesday, Dec. 11 at 7:30 a.m.:

• Researchers to Present Event-free and Overall Survival Results From NeoALTTO Trial;
• High Levels of Immune Cells in Tumors May Identify Breast Cancer Patients Most Likely to Benefit From Trastuzumab; and
• Study Identifies Highly Effective Treatment Option for Patients with HER2-positive Breast Cancer.
Wednesday, Dec. 11 at 12:30 p.m.:
• Avoiding Radiotherapy is an Option for Some Older Patients;
• Benefit of Breast Cancer Screening More Consistent Across Studies Than Previously Understood; and
• Patients With Metastatic Breast Cancer May Not Benefit From Surgery and Radiation After Chemotherapy.

Thursday, Dec. 12 at 7:30 a.m.:

• PIK3CA Gene Mutations Make HER2- and Hormone Receptor-positive Breast Cancers Treatment-resistant;
• Exercise Improves Drug-associated Joint Pain in Breast Cancer Survivors;
• New Drug Combination Delayed Disease Progression for Subgroup of Women With Metastatic Breast Cancer; and
• Antihormone Therapy Anastrozole May Provide New Option for Breast Cancer Prevention.

Friday, Dec. 13 at 7:30 a.m.:

• Changing Chemotherapy Not Beneficial for Metastatic Breast Cancer Patients With Elevated Circulating Tumor Cells;
• New Presurgery Combination Therapy May Improve Outcomes for Women With Triple-negative Breast Cancer
• New Combination Therapy Fails to Delay Progression of Advanced Breast Cancer;
• Bisphosphonate Treatment Fails to Improve Outcomes for Women With Chemoresistant Breast Cancer; and
• New Presurgery Treatment Combination More Effective for Women with Triple-negative Breast Cancer.

The press room will be in Room 217A/B. To register as press for the conference and for more information, go to

The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio is one of the elite academic cancer centers in the country to be named a National Cancer Institute (NCI) Designated Cancer Center, and is one of only four in Texas. A leader in developing new drugs to treat cancer, the CTRC Institute for Drug Development (IDD) conducts one of the largest oncology Phase I clinical drug programs in the world, and participates in development of cancer drugs approved by the U.S. Food & Drug Administration. For more information, visit

Share This Article!